Brain Cancer
Page 1 • 3 itemsGlobal brain cancer market intelligence for pharma BD, investors & analysts. Track drug development, clinical trials, and regulatory approvals.
Arvinas Receives FDA Approval for VEPPANU (Vepdegestrant), First PROTAC Drug for ESR1-Mutated Breast Cancer
Arvinas announces FDA approval of VEPPANU, the first PROTAC protein degrader for ESR1-mutated, ER+/HER2- advanced breast cancer treatment.
Mabwell's 9MW2821 Becomes First Nectin-4 ADC to Enter Phase III Trial for Triple-Negative Breast Cancer
Mabwell initiates Phase III trial for 9MW2821, the world's first Nectin-4-targeting ADC to reach pivotal testing for triple-negative breast cancer treatment.
Olema Oncology Presents Palazestrant and OP-3136 Preclinical Data at AACR 2026 for Breast Cancer Treatment
Olema Oncology shares new preclinical data for palazestrant SERD therapy and OP-3136 combination at AACR 2026, advancing breast cancer treatment options.